Stockscreener 앱 받기
23.99
0.46%
0.11
시간 외 거래:
24.00
0.01
+0.04%
전일 마감가:
$23.88
열려 있는:
$24.1
하루 거래량:
110.15K
Relative Volume:
0.74
시가총액:
$352.13M
수익:
-
순이익/손실:
$-19.48M
주가수익비율:
-16.39
EPS:
-1.4641
순현금흐름:
$-8.59M
1주 성능:
+8.50%
1개월 성능:
-11.83%
6개월 성능:
+123.37%
1년 성능:
+165.67%
1일 변동 폭
$23.99
$25.50
1주일 범위
$21.92
$25.50
52주 변동 폭
$7.78
$34.10
그리니치 Stock (GLSI) Company Profile
명칭
Greenwich Lifesciences Inc
전화
203-434-3290
주소
3992 BLUEBONNET DR, BUILDING 14, STAFFORD
Compare GLSI vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GLSI
Greenwich Lifesciences Inc
|
23.99 | 343.62M | 0 | -19.48M | -8.59M | -1.4641 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
그리니치 Stock (GLSI) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-20 | 개시 | Noble Capital Markets | Outperform |
| 2021-09-01 | 개시 | H.C. Wainwright | Buy |
그리니치 주식(GLSI)의 최신 뉴스
Technical Reactions to GLSI Trends in Macro Strategies - Stock Traders Daily
Greenwich LifeSciences, Inc. Q1 2026 Quarterly Report: Financials, Risk Factors, and Disclosure Highlights - Minichart
Trading the Move, Not the Narrative: (GLSI) Edition - Stock Traders Daily
Greenwich LifeSciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Greenwich LifeSciences (GLSI) loss widens as ATM equity raises fund trials - Stock Titan
What’s Driving GLSI Stock Today? - Stocktwits
These 10 small-cap U.S. healthcare companies carry the market's most expensive valuations - Seeking Alpha
Greenwich LifeSciences, Inc. 2024 Annual Report: Breast Cancer Immunotherapy Pipeline, Clinical Trials, and Regulatory Risks - minichart.com.sg
GREENWICH LIFESCIENCES ($GLSI) Releases Q4 2025 Earnings - Quiver Quantitative
Greenwich LifeSciences FY 2025: Net loss $19.4M, No revenue — 10-K Summary - TradingView
Greenwich LifeSciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Greenwich LifeSciences delays 10-K filing, cites audit coordination By Investing.com - Investing.com Nigeria
Greenwich LifeSciences presents immune response data at ASCO - Investing.com
Greenwich LifeSciences presents immune response data at ASCO By Investing.com - Investing.com South Africa
Breast cancer trial: GLSI-100 shots spark injection-site reactions over time - Stock Titan
GLSI Stock Climbs After Removing A Key Overhang – Retail Turns Focus To High-Stakes Breast Cancer Trial - TradingView
Greenwich LifeSciences Says Audit of 2025 Form 10-K Filing in Final Stages of Approval - Moomoo
Greenwich Lifesciences Provides Update Regarding Form 10-K Filing - TradingView
Greenwich LifeSciences updates on Form 10-K filing progress - Traders Union
Greenwich LifeSciences Provides Update Regarding Form 10-K Filing - The Manila Times
Greenwich LifeSciences, Inc. Provides Update on 2025 Form 10-K Filing and Phase III Clinical Trial Progress - Quiver Quantitative
Greenwich LifeSciences delays 10-K filing, cites audit coordination - Investing.com
Breast cancer trial firm details audit delay, $10.5M cash - Stock Titan
Auddia’s Discovr Radio Forms AI-Driven Partnership With Beatcave to Expand Independent Artist Discovery Across Canada - Weekly Voice
Greenwich LifeSciences, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Greenwich LifeSciences (GLSI) Drops Nearly 10%: Key Support and Resistance Levels in FocusInsider Selling Alerts - The Legal Advocate
GLSI Q3 2025 Earnings: Narrower-than-Expected Loss as Biotech Advances Clinical PipelineLow Growth Earnings - newsline.com
Greenwich LifeSciences (GLSI) Slips Marginally as Stock Holds Above Key SupportIchimoku Kumo Twist - The Legal Advocate
Greenwich LifeSciences Inc. (GLSI) Q3 2025 Earnings: Narrowed Loss Highlights Progress in Immunotherapy DevelopmentQuarterly Earnings - newsline.com
Greenwich LifeSciences (GLSI) Surges 7% as Biotech Momentum BuildsHigh Dividend Factor - newsline.com
GLSI Technical Analysis | Trend, Signals & Chart Patterns | GREENWICH LIFESCIENCES INC (NASDAQ:GLSI) - ChartMill
Greenwich LifeSciences Inc. (GLSI) Edges Higher as Shares Approach Key ResistanceDouble EMA - The Legal Advocate
(GLSI) Volatility Zones as Tactical Triggers - Stock Traders Daily
Greenwich LifeSciences receives Nasdaq notice regarding late Form 10-Q filing - MSN
Greenwich LifeSciences receives Nasdaq noncompliance notice By Investing.com - Investing.com Nigeria
Greenwich LifeSciences: Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing - Moomoo
Greenwich LifeSciences receives Nasdaq noncompliance notice - Investing.com
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Weekly Voice
Greenwich LifeSciences Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing - Weekly Voice
Greenwich Lifesciences Inc expected to post a loss of 32 cents a shareEarnings Preview - TradingView
Price-Driven Insight from (GLSI) for Rule-Based Strategy - Stock Traders Daily
Greenwich LifeSciences (NASDAQ:GLSI) Upgraded by Wall Street Zen to Hold Rating - MarketBeat
Greenwich LifeSciences (GLSI) shares fall 3% despite tiny EPS beat; investors demand clinical progress updates. - newser.com
(GLSI) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Greenwich LifeSciences delays annual report filing - Investing.com UK
그리니치 (GLSI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
그리니치 주식 (GLSI) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Patel Snehal | CEO and CFO |
Jan 12 '26 |
Buy |
27.54 |
2,900 |
79,866 |
5,602,302 |
| Patel Snehal | CEO and CFO |
Dec 31 '25 |
Buy |
21.36 |
4,300 |
91,848 |
5,599,402 |
| Patel Snehal | CEO and CFO |
Dec 30 '25 |
Buy |
21.73 |
2,900 |
63,017 |
5,595,102 |
| Patel Snehal | CEO and CFO |
Dec 18 '25 |
Buy |
12.62 |
4,100 |
51,742 |
5,592,202 |
| Patel Snehal | CEO and CFO |
Nov 25 '25 |
Buy |
8.37 |
4,600 |
38,502 |
5,588,102 |
| Patel Snehal | CEO and CFO |
Nov 07 '25 |
Buy |
8.43 |
10,600 |
89,358 |
5,583,502 |
| Patel Snehal | CEO and CFO |
Oct 31 '25 |
Buy |
9.26 |
2,300 |
21,298 |
5,572,902 |
2.60%
0.94%
자본화:
|
볼륨(24시간):